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PLINICAL RESEARCH Clinical Trial
ardiovascular Morbidity and Mortality
n the Atherosclerosis and Folic Acid
upplementation Trial (ASFAST) in Chronic Renal Failure
Multicenter, Randomized, Controlled Trial
ophia Zoungas, MBBS,* Barry P. McGrath, MBBS, MD,* Pauline Branley, BMED, PHD,†
eter G. Kerr, MBBS, PHD,‡ Christine Muske, BSCI(NURS),† Rory Wolfe, PHD,†
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rian G. Hutchison, MBBS,¶ Robert Walker, MBCHB, MD,# John J. McNeil, MBBS, PHD†
andenong, Melbourne, Clayton, Parkville, Heidelberg, and Perth, Australia; and Dunedin, New Zealand
OBJECTIVES The Atherosclerosis and Folic Acid Supplementation Trial (ASFAST) aimed to establish
whether high-dose folic acid would slow the progression of atherosclerosis and reduce
cardiovascular events in patients with chronic renal failure (CRF).
BACKGROUND Hyperhomocysteinemia is a potential contributor to the high rates of cardiovascular morbidity
and mortality in patients with CRF.
METHODS A total of 315 subjects with CRF, mean age 57 years (range 24 to 79 years) were randomized
to 15 mg folic acid daily or placebo and followed for a median of 3.6 years. The primary
intima-media thickness (IMT) and clinical end points were: rate of progression of mean
maximum carotid IMT and a composite of myocardial infarction (MI), stroke, and
cardiovascular death. Secondary end points included all cardiovascular events and change in
pulse wave velocity, systemic arterial compliance and augmentation index. Data were analyzed
by intention-to-treat.
RESULTS Plasma total homocysteine was reduced by 19% in the folic acid group. There was no
significant difference between the treatment groups in rate of change of IMT or any measure
of artery function. Seventy-seven events occurred in the folic acid group (14.9 per 100
patient-years) as compared with 86 in the placebo group (16.3 per 100 patient-years). The
rates of the primary and secondary clinical end points at five years were not significantly
different after adjustment for baseline differences between the groups (adjusted hazard ratio
for MI, stroke, and cardiovascular death: 0.98 [95% confidence interval: 0.66 to 1.47]; p 
0.94; for all cardiovascular events: 0.95 [95% confidence interval: 0.69 to 1.30]; p  0.75).
CONCLUSIONS High-dose folic acid does not slow atheroma progression or improve cardiovascular morbidity
or mortality in patients with CRF. (J Am Coll Cardiol 2006;47:1108–16) © 2006 by the
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.10.064American College of Cardiology Foundation
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ohronic renal failure (CRF) is a risk factor for accelerated
ardiovascular disease. Age-adjusted cardiovascular mortal-
ty rates are 10 to 20 times greater in patients with CRF
han the general population (1). More than one-half of all
ialysis-related deaths are cardiovascular in nature (2–4).
Homocysteine, a nonessential sulphur-containing amino
cid, accumulates in CRF owing to both altered metabolism
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ealth, Monash University, Dandenong Hospital, Dandenong, Victoria, Australia;
Department of Epidemiology and Preventive Medicine, Monash University, Alfred
ospital, Melbourne, Victoria, Australia; ‡Department of Nephrology, Monash
edical Centre, Clayton, Victoria, Australia; §Department of Nephrology, Royal
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ourne, Melbourne, Victoria, Australia; Department of Nephrology, Austin Health,
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ospital, Perth, Western Australia, Australia; and the #Department of Nephrology,
unedin Hospital, Dunedin, New Zealand. This study was supported by grants-in-
id from the National Health and Medical Research Council of Australia and
ational Kidney Foundation of New Zealand.i
Manuscript received June 22, 2005; revised manuscript received September 30,
005, accepted October 3, 2005.5) and reduced renal excretion (6). Approximately 85% of
atients with CRF have elevated homocysteine levels (6).
Population studies have reported an association between
ild hyperhomocysteinemia and occlusive vascular disease,
lthough the findings are inconsistent (7–9). Levels of homo-
ysteine and cardiovascular disease have also been linked to
olate status (5).
In CRF, observational studies have suggested a causal
ssociation between hyperhomocysteinemia and cardiovas-
ular disease (10,11). Intervention studies are necessary to
etermine whether the relationship is causal and whether
owering of plasma homocysteine reduces the incidence of
ardiovascular events in patients with CRF (12).
Randomized controlled trials of homocysteine-lowering
herapy have given inconsistent results, with reports of
educed carotid IMT progression (13,14), improvement in
xercise-electrocardiogram responses (15), a decreased rate
f restenosis and adverse events after percutaneous coronary
ntervention (16,17), and an increased rate of restenosis and
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March 21, 2006:1108–16 Final Results of the ASFAST Studydverse events after coronary stent placement (18). In
atients treated with a multivitamin containing folic acid
fter ischemic stroke, no benefit in cardiovascular outcome
as found (19).
The Atherosclerosis and Folic Acid Supplementation
rial (ASFAST) was a multicenter, randomized, double-
lind, placebo-controlled trial of high-dose folic acid ther-
py in patients with CRF, examining the hypothesis that
ardiovascular disease and atheroma progression in CRF is
elated to hyperhomocysteinemia and can be reduced by
owering homocysteine with folic acid therapy.
In brief, the study aims were to determine whether
igh-dose folic acid supplementation would slow the pro-
ression of carotid artery intima-media thickness (IMT)
nd reduce the incidence of cardiovascular events (a com-
osite end point of myocardial infarction, stroke, and death
rom cardiovascular cause) in this population. The differ-
nces between the treatment groups in all fatal and nonfatal
ardiovascular events and indices of arterial function (pulse
ave velocity [PWV], systemic arterial compliance [SAC],
nd augmentation index [AIx]) were also studied.
ETHODS
tudy design. The double-blind randomized study evalu-
ted daily 15 mg folic acid or identical placebo in 315
atients with end-stage renal disease. The detailed protocol
ncluding study design, rationale, organization, measure-
ents, power calculations, and baseline results have been
ublished previously (20).
ubjects. Men and women aged over 18 years with CRF of
ny cause, a serum creatinine of 0.40 mmol/l or greater
creatinine clearance25 ml/min), and either awaiting dialysis
r already treated with continuous ambulatory peritoneal dial-
sis, intermittent peritoneal dialysis, or hemodialysis were
ligible for the study.
Three hundred fifteen patients who met the entry criteria
ere randomly assigned to either 15 mg of folic acid daily or
dentical placebo. At entry, those being treated with folic
cid or multivitamins containing folic acid were required to
ithdraw treatment; patients with folate deficiency requir-
ng supplementation were excluded. The study medication
as dispensed in identical containers with neither study
Abbreviations and Acronyms
AIx  augmentation index
ASFAST  Atherosclerosis and Folic Acid
Supplementation Trial
CI  confidence interval
CRF  chronic renal failure
GEE  generalized estimating equation
IMT  intima-media thickness
PWV  pulse wave velocity
SAC  systemic arterial compliance
tHcy  total plasma homocysteinetaff nor participant aware of treatment allocation. Study monsultations, including carotid IMT measurement, oc-
urred at yearly intervals with treatment scheduled to last
ve years.
tudy conduct and organization. Recruitment com-
enced on June 30, 1998, and was closed on December 31,
000. Four renal units in Australia and one in New Zealand
articipated. The ethics review board at each institution
pproved the protocol, and the study was conducted in
ccordance with the National Health and Medical Research
ouncil of Australia Guidelines on Human Experimenta-
ion. An independent steering and safety committee super-
ised the study.
Folate replacement was not allowed during the study.
owever any participant found to have red cell folate levels
elow 510 nmol/l on six monthly tests (normal range: 510 to
,310 nmol/l) were allowed folic acid supplementation, at
he smallest dose required to normalize the level, and
ontinued in the study.
The study was terminated on December 31, 2003, and all
ortality and morbidity to this date were ascertained for
11 (99%) of the 315 participants randomized. Subjects
ho underwent renal transplantation during follow-up were
ensored at the time of transplantation. This was deemed
ecessary because of the effect of transplantation per se on
ardiovascular survival.
nd points. The primary IMT end point was change in
he rate of progression of mean maximum carotid artery
MT. The main clinical end point was a composite of
yocardial infarction, stroke, and death from cardiovascular
ause. Both first and subsequent cardiovascular events were
ncluded. Secondary end points included all fatal and
onfatal cardiovascular events, including myocardial infarc-
ion, stroke, unstable angina, revascularization, and periph-
ral vascular disease. Changes in PWV, SAC, and AIx were
lso assessed. All clinical end points were subject to an
ndependent adjudication process by an endpoint monitor-
ng committee.
easurement of carotid IMT. The IMT of the common
arotid artery was measured using a high-resolution ultra-
ound machine (DRF-400, Diasonics, Santa Clara, Califor-
ia) with a handheld 7.5-MHz transducer (7.5-SPC me-
hanic sector transducer, Diasonics). All measurements
ere performed in the same study laboratory in each major
ity center, and a single reference laboratory performed all
mage analyses.
In brief, a region 1.0 cm proximal to the origin of the bulb
f both common carotid arteries was identified by B-mode
ltrasonography. Three images of each B-mode, taken at
hree different angles (anterior, lateral, medial), were re-
orded, digitized, and saved for subsequent analysis. The 60
easurements from the far wall of both common carotid
rteries were used in the final data analysis to give mean
aximum and mean IMT values.
easurements of arterial function. A subgroup of sub-
ects (n  207) from two study centers underwent measure-
ent of indices of arterial stiffness and compliance includ-
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Final Results of the ASFAST Study March 21, 2006:1108–16ng: PWV, the speed of travel of the pressure pulse along an
rterial segment; SAC, the relationship between change in
olume and change in pressure during diastole; and AIx, the
ercentage contribution of reflected waves to peak central
ressure. Details of these methods have been given previ-
usly (20).
epeatability. Two operators performed all image reading
f IMT and analysis of arterial function indexes. The
ntraobserver correlation coefficient for IMT was 0.89, the
oefficient of variation was 10.4%, and the interobserver
orrelation coefficient was 0.88. The intraclass correlation
oefficients (95% confidence interval [CI], number of ob-
ervations) were: IMT 0.85 (0.72 to 0.97; n  40); PWV
.95 (0.91 to 0.99; n  46); SAC 0.92 (0.86 to 0.99; n 
2); and AIx 0.98 (0.97 to 0.99; n  42).
tatistical analysis. The sample size of the study was based
n IMT progression. Using a predicted 0.03 mm IMT
ncrease over three years in the placebo group, i.e., 0.01Figure 1. Triam/year progression, with an estimated standard deviation
SD) of 0.01 mm/year, the study was powered to detect a
3% slower rate of progression in the folic acid group, at a
ignificance level (alpha) of 0.05 (two-sided) with 80%
ower. The number of subjects required in each treatment
rm was 143, that is 286 subjects to be followed for three
ears.
Assuming a cardiovascular event/death rate in the placebo
roup of 1.5 events per 10 person-years of follow up, a mean
ollow-up duration of three years per participant (858
erson-years of follow-up in total) and a two-sided signif-
cance level (alpha) of 0.05, the study had approximately
1% power to detect a 50% reduction in the rate of major
ardiovascular events in the folic acid group.
A semiparametric linear regression model was fitted to
ean maximum IMT with an interaction between study
rm and time on study (years), assuming linear change over
ime. The method of generalized estimating equationsl profile.
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March 21, 2006:1108–16 Final Results of the ASFAST StudyGEE) (21) with an exchangeable working correlation
atrix was used to estimate the parameters of this model
hile taking into account possible within-person correlation
n mean maximum IMT measurements over time. The
tandard errors calculated by the GEE method are robust to
isspecification of the correlation and variance parts of the
odel (21). Adjustments in the model were made for the
ollowing baseline factors found to be related to death/
ransplant propensity (age, diastolic blood pressure, diabe-
es, past cardiovascular disease, and antiplatelet agent use)
ere then included.
The primary analysis used only observed data and as-
umed that missing data was missing at random (22). To
ssess the possible impact of this assumption which is
overned by patient dropout, mean maximum IMT was
e-analyzed with stratification by time of dropout with
espect to IMT measurement.
Survival curves were constructed according to the
aplan-Meier method. Event rates were compared between
reatment groups using Cox proportional hazard regression
odels. Adjusted hazard ratios were calculated by the same
ethod to allow for imbalances in the treatment groups at
tudy entry.
The GEE method described above was used to compare
otal plasma homocysteine (tHcy) levels between study arms
cross the follow-up times without assuming a linear change
ver time, i.e., performing comparisons at each follow-up
ime point. A Spearman correlation coefficient was used to
escribe the relationship between plasma tHcy and red cell
olate levels. Analysis of covariance was used to compare
2-month PWV, SAC, and AIx between study arms with
djustment for baseline values and assuming that missing
easurements were missing at random. The 12-month time
oint was chosen because it was anticipated that any
reatment effect should have been evident by that time.
Data were analyzed on an intention-to-treat basis, i.e.,
ccording to allocated treatment group and irrespective of
ompliance with treatment. Statistical significance is con-
rmed when p values are 0.05. All analyses were per-
ormed in Stata Statistical Software, Release 7.0 (Stata
orp., College Station, Texas).
ESULTS
ubjects. Three hundred fifteen subjects were recruited
ver a two-year period and followed for a median of 3.6
ears, providing a total of 1,044 patient-years of observa-
ion. One hundred fifty-six subjects were assigned to 15 mg
olic acid daily and 159 to identical placebo. During
ollow-up, 71 subjects discontinued treatment (41 from folic
cid group, 30 from placebo group) and 80 had renal
ransplantation (37 from folic acid group, 43 from placebo
roup). As shown in Figure 1, all randomized subjects were
A
hncluded up to the time of death, transplantation, or closure
f the study.
aseline data. The baseline characteristics of the 315
articipants are shown in Table 1. At study entry, the
roportion of women in the placebo group was greater than
n the folic acid group (37.7% vs. 26.9%). With respect to
ge, mode of dialysis, cardiovascular risk factor profile,
edical therapy, and fasting biochemistry, the two groups
ere closely matched except for use of antiplatelet agents,
hich was greater in the placebo than in the folic acid group
31.4% vs. 21.8%).
Of the 102 women and 213 men studied, 35% reported a
istory of cardiovascular disease (angina [32%], acute myo-
ardial infarction [11%], and/or cerebrovascular disease
9%]), 90% hypertension, 23% diabetes mellitus, and 44%
ypercholesterolemia.
able 1. Baseline Characteristics of the Patients
Characteristic
Folic Acid
Group
(n  156)
Placebo
Group
(n  159)
ge, yrs 56  13 56  14
emale, n (%) 42 (26.9) 60 (37.7)
ialysis mode, n (%)
Predialysis 20 (12.8) 28 (17.6)
Hemodialysis 102 (65.4) 90 (56.6)
Peritoneal dialysis 34 (21.8) 41 (25.8)
lood pressure
Systolic blood pressure 144  24 141  23
Diastolic blood pressure 83  13 79  13
eart rate, beats/min 76  13 75  13
ody mass index, kg/m2 26  5 27  4
aist-hip ratio 0.96  0.10 0.95  0.09
edical history, n (%)
Coronary artery disease
AMI 18 (11.5) 17 (10.7)
Angina 49 (31.4) 49 (30.8)
Stroke or transient ischemic attacks 13 (8.3) 14 (8.8)
Peripheral vascular disease 34 (21.8) 32 (20.1)
Hypertension 141 (90.4) 144 (90.6)
Current cigarette smoking 16 (10.3) 15 (9.4)
Diabetes mellitus 36 (23.1) 37 (23.3)
Hypercholesterolemia 67 (42.9) 73 (45.9)
edications, n (%)
Folic acid 57 (36.5) 56 (35.2)
ACE inhibitors/angiotensin II blockers 42 (26.9) 40 (25.2)
Beta-blockers 41 (26.3) 42 (26.4)
Calcium-channel blockers 60 (38.5) 66 (41.5)
Diuretics 32 (20.5) 33 (20.8)
Antiplatelet agents 34 (21.8) 50 (31.4)
Lipid-lowering agents 45 (28.8) 46 (28.9)
Oral anticoagulants 8 (5.1) 11 (6.9)
otal plasma homocysteine, mol/l 27  12 27  14
otal cholesterol, mmol/l 5.1  1.2 5.3  1.2
DL cholesterol, mmol/l 3.2  1.0 3.3  1.0
DL cholesterol, mmol/l 1.1  0.4 1.1  0.4
riglycerides, mmol/l 2.1  1.4 2.1  1.1
arotid intima-media thickness, mm
Mean, maximum 1.06  0.23 1.08  0.28
Mean 0.86  0.17 0.86  0.20CE  angiotensin-converting enzyme; AMI  acute myocardial infarction; HDL 
igh-density lipoprotein; LDL  low-density lipoprotein.
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Final Results of the ASFAST Study March 21, 2006:1108–16ffects of treatment on tHcy and red cell folate. At the
nd of follow-up, 17 participants (5%) had received addi-
ional folic acid therapy (10 [6%] in the placebo group and
[4%] in the folic acid group; dose range 0.3 to 5 mg;
edian 0.7 mg daily) for the treatment of folate deficiency
red cell folate levels below 510 nmol/l; 8 in the placebo
roup) or on the basis of treating physician request (2 in the
lacebo group and 7 in the folic acid group).
The tHcy levels over time are shown in Figure 2. At
aseline, median tHcy and red cell folate levels were similar
etween the treatment groups (folic acid group vs. placebo
roup: 24.6 vs. 25.1 mol/l tHcy; 1,354 vs. 1,186 nmol/l red
ell folate). After 12 and 36 months of follow-up the
edian tHcy levels were 19.9 and 21.5 mol/l, respectively,
n the folic acid group compared with 24.4 and 23.9 mol/l,
espectively, in the placebo group (normal range: 3 to 13
mol/l). At 12 months, 10.9% of the folic acid group had
chieved normal tHcy levels as compared with 1.6% of the
lacebo group. Estimated difference in mean tHcy between
reatment groups at 12 months was 7.5 (95% CI: 10.4
o4.6; p 0.001); at 24 months7.1 (95% CI:10.2 to
igure 2. Mean total plasma homocysteine levels (bars  1 standard de
nalysis of covariance on homocysteine at median follow-up (3.6 years) ad
able 2. Mean  Standard Deviation of Changes in Mean Maxi
o Patients’ Final Visit Before Exiting the Study
Treatment
Group
Time of Patient’s Fin
1 2 3
lacebo (n*) 0.022  0.204 (38) 0.016  0.094 (20) 0.015  0.1
olic acid (n*) 0.029  0.296 (33) 0.010  0.078 (28) 0.042  0.1Number of patients exiting study at specified times.4.0; p 0.001); at 36 months2.4 (95% CI:6.8 to 1.9;
 0.27); and at 48 months 4.7 (95% CI: 9.4 to 0.1;
 0.05).
The median red cell folate levels increased three-fold in
he folic acid group and were unchanged in the placebo
roup (folic acid group vs. placebo group: 3,819 vs. 1,159
mol/l) and remained elevated in the folic acid group after
6 months (folic acid group vs. placebo group: 2,797 vs.
,509 nmol/l). The tHcy levels was inversely correlated with
ed cell folate levels (Spearman correlation r  0.35; p 
.001).
arotid IMT. At baseline, carotid IMT was not signifi-
antly different between the treatment groups (mean  SD,
olic acid group vs. placebo group: 1.06  0.23 mm vs.
.08  0.28 mm; p  0.75).
Mean change in IMT from baseline to follow-up is
hown in Table 2. There was no significant difference in the
ate of progression of mean maximum IMT between the
reatment groups (0.01 mm/year, 95% CI: 0.01 to 0.03;
 0.43). Further analysis stratified by time of drop-out
lso showed no significant difference in overall IMT change
) over time, by treatment group. The p value is for treatment effect from
for baseline homocysteine.
Carotid Intima-Media Thickness (mm) From Baseline
dy Visit (yrs)
Overall4 5
) 0.003  0.082 (23) 0.017  0.065 (22) 0.030  0.136 (125)
) 0.011  0.044 (20) 0.020  0.045 (16) 0.020  0.170 (119)viationmum
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20 (22
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March 21, 2006:1108–16 Final Results of the ASFAST Studyer year between the treatment groups (mean change SD:
.03  0.14 mm/year in the placebo group vs. 0.02 
.17 mm/year in the folic acid group; p  0.82).
For subjects who dropped out early (after visit 1 or 2)
ecause of death, IMT increased (mean change  SD:
.05  0.24 mm/year), whereas for subjects followed for
onger (drop-out after visit 3 or 4) or complete follow-up
MT decreased (mean change  SD: 0.02  0.09 mm/
ear). The difference in IMT progression between those
ying early during follow-up and those surviving longer was
.07 mm/year (95% CI: 0.02 to 0.12 mm/year; p  0.01).
ardiovascular events. The rates of all fatal and nonfatal
ardiovascular events in the two treatment groups are shown
n Table 3. Seventy-seven events occurred in the folic acid
roup (14.9 per 100 patient-years) and 86 in the placebo
roup (16.3 per 100 patient-years). Of these events, 44
57%) were first events in the folic acid group (9.6 per 100
atient-years) as compared with 53 (62%) in the placebo
roup (11.7 per 100 patient-years).
Regarding the composite end point of myocardial infarc-
ion, stroke, and cardiovascular death, the rate of events in
he folic acid group was 6.1 first events and 9.3 total events
er 100 patient-years as compared with 8.3 first events and
0.2 total events per 100 patient-years in the placebo group.
he difference, however, was not significant (hazard ratios
or first and total events: 0.71 [95% CI: 0.42 to 1.21]; p 
.21; and 0.85 [95% CI: 0.58 to 1.26]; p  0.43; respec-
ively). After adjustment for baseline differences in gender,
iastolic blood pressure, and aspirin use, hazard ratio for
rst myocardial infarction, stroke, and cardiovascular death
as 0.93 (95% CI: 0.58 to 1.48); p  0.75; adjusted hazard
atio for all myocardial infarction, stroke, and cardiovascular
eath was 0.98 (95% CI: 0.66 to 1.47); p  0.94 (Fig. 3).
The incidence of all fatal and nonfatal cardiovascular
able 3. Incidence of Primary and Secondary Outcomes
Outcome
Folic Acid Grou
(n  156)
No. of
Events
Rate pe
Patien
rimary end points
First myocardial infarction, stroke or death
from cardiovascular cause
33 6.
All myocardial infarction, stroke or death
from cardiovascular cause
46 8.
econdary end points
First cardiovascular event or death from
cardiovascular cause
44 9.
All cardiovascular events or death from
cardiovascular cause
77 14.
Death from cardiovascular causes 21
Coronary event 23
Cerebrovascular event 8
Revascularization 11
Peripheral vascular events 14
Adjusted for gender, antiplatelet use, and diastolic blood pressure.
CI  confidence interval.vents was not significantly different between groups. The
d
pisk reduction was not significant after adjustment for
aseline differences in gender, diastolic blood pressure, and
spirin use (adjusted hazard ratio for all first cardiovascular
vents: 0.89 [95% CI: 0.59 to 1.34]; p  0.57; adjusted
azard ratio for all recurrent cardiovascular events: 0.95
95% CI: 0.69 to 1.30]; p  0.75).
rterial indices. After 12 months of treatment there was
o significant difference between the groups in mean
WV(a  f) (difference in means: 0.31 m/s [95% CI:
1.20 to 0.57]; p 0.49), SAC (difference in means: 0.022
/mm Hg [95% CI: 0.046 to 0.090]; p  0.52), or AIx
difference in means: 0.1% [95% CI: 5.3 to 5.5]; p 
.97).
igure 3. Survival to first myocardial infarction, stroke, or cardiovascular
Placebo Group
(n  159)
Hazard Ratio
(95% CI)* p Value
No. of
Events
Rate per 100
Patient-yrs
40 8.2 0.93 (0.58–1.48) 0.75
55 10.4 0.98 (0.66–1.47) 0.94
53 11.7 0.87 (0.58–1.32) 0.52
86 16.3 0.95 (0.69–1.30) 0.75
24
19
18
5
20p
r 100
t-yrs
7
9
6
9eath by treatment group. Red line  folic acid group; black line 
lacebo group.
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Final Results of the ASFAST Study March 21, 2006:1108–16reatment safety. Twenty-five percent of patients in the
olic acid group and 18% in the placebo group stopped
aking their treatment because of adverse effects (6 in folic
cid group; 2 in placebo group) or unwillingness to continue
20 in folic acid group; 12 in placebo group). No serious
dverse effects were reported during the study. In 12
ubjects (6 in folic acid group; 6 in placebo group), co-
alamin deficiency (160 pmol/l) was detected and led to
eplacement.
ISCUSSION
bservational studies have suggested a causal relationship
etween hyperhomocysteinemia and cardiovascular morbid-
ty in the general population (7,8) and in patients with CRF
11,23). Folic acid can reduce elevated homocysteine levels
24–28) but has not yet been shown to improve atheroma
rogression or cardiovascular outcome in CRF.
Elevated homocysteine levels in the general population
ave been related to carotid IMT measurements (29,30). In
RF as well, higher carotid IMT measurements have been
ssociated with high levels of homocysteine (31). Small
tudies with limited follow-up have reported a decrease in
arotid IMT progression with vitamin supplementation
ith folic acid in renal transplant recipients (13) and in
igh-risk vascular patients (14).
In the present cohort of CRF patients we did not find a
elationship between baseline carotid IMT and homocys-
eine level (20). Despite modest homocysteine lowering,
igh-dose folic acid therapy had no effect on atheroma
rogression, measured by mean maximum carotid IMT,
ver the five-year period.
Mean maximum IMT increased in both treatment groups
or the first two years and thereafter reduced slightly. One
xplanation is that those with the greatest risk for atheroma
rogression and clinical events may have dropped out early.
n long-term intervention studies the greatest limitation
ith following IMT is missing data in subjects having fatal
vents (32). In this study the finding that IMT was
ncreased in those dropping out early because of death, and
ecreased in those followed for longer, supports this. An-
ther possible explanation is that the increase in IMT over
ime was attenuated by dilatation of the carotid artery.
arotid diameter was not measured in our subjects.
A small dose-response study of folic acid therapy in CRF
uggested no difference in cardiovascular morbidity or all-
ause mortality among patients taking between 1 and 15 mg
olic acid daily (12). That small study had no placebo arm.
n the present study, after adjustment for baseline differ-
nces in gender, diastolic blood pressure, and aspirin use,
here was no significant difference in cardiovascular events
or those treated with high-dose folic acid compared with
lacebo. The all-event confidence intervals suggest that a
eduction of greater than 34% in the event rate owing to
olic acid could be excluded. pWe observed no effect of treatment with folic acid on any
ndex of arterial stiffness or compliance. This finding is
onsistent with the observed lack of effect of folic acid on
MT progression and is contrary to the hypothesis that
rterial disease in CRF is related to hyperhomocysteinemia
nd can be improved by homocysteine lowering. It also
uggests that folic acid does not improve arterial function in
atients with CRF independent of its homocysteine effect.
There are several possible reasons for the negative find-
ngs in this study. They include: homocysteine is not related
o vascular disease progression in CRF; there was insuffi-
ient lowering of homocysteine to be of biologic signifi-
ance; the dose or duration of treatment with folic acid was
nsufficient; and the study had insufficient statistical power,
problem aggravated by the high withdrawal and transplan-
ation rates and folate replacement policy.
Arterial vascular disease in CRF was associated with
raditional cardiovascular risk factors, but also with systemic
nflammation. Malnutrition has also been implicated in low
omocysteine levels (5). This has led to the suggestion that
omocysteine is only a marker of cardiovascular disease in
RF and not a pathogenic factor.
After 12 months of folic acid treatment, there was a 19%
ecrease in total homocysteine levels in the folic acid group;
evels were normalized in only 10.9%. This was maintained
or up to 36 months and associated with a three-fold
ncrease in red cell folate levels. In the placebo group there
as no significant change in total homocysteine or red cell
olate levels.
The failure of homocysteine levels to normalize with folic
cid therapy in patients with CRF, despite markedly in-
reased red cell folate levels, has previously been described
27). Possible explanations include impaired cellular uptake
nd utilization of folate metabolites (33), restricted intra-
ellular capacity and saturation of the remethylation path-
ay (34), and reduction in plasma clearance of homocys-
eine (35). Touam et al. (36) suggested that the folate
esistance could be overcome with the use of L-5-
ormyltetrahydrofolate; their result could not be replicated
y others with the use of L-5-methyltetrahydrofolate (37).
In the present study, failure to normalize homocysteine
evels was not explained by concurrent cobalamin deficiency,
ecause all our patients were required to have normal levels
f cobalamin, which was monitored throughout the trial.
thers have studied treatment with pyridoxine (26,38),
erine (39), betaine (40,41), and N-acetylcysteine (42) and
imilarly have shown no additional effect on homocysteine
evels in dialyzed patients. The challenge remains to identify
therapy which can normalize homocysteine levels in
atients with CRF.
onclusions. Folic acid at a dose of 15 mg daily had no
ignificant effect on atheroma progression nor did it improve
ardiovascular outcome for patients with CRF. There was
lso no improvement in any index of artery function.
omocysteine levels were lowered but not normalized. It isossible that a treatment effect of 33% was missed.
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rotection in chronic renal failure cannot be advocated on
he basis of these findings.
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